Urology Textbook
Clinical Essentials
By Dirk Manski, MD

 You are here: Urology Textbook > Prostate > Prostate cancer > Radical prostatectomy

Prostate Cancer: Treatment by Radical Prostatectomy


Guidelines and review literature: (EAU Guidelines Prostate Cancer) (S3-Leitlinie Prostatakarzinom) (Walsh-Campbell Urology 11th Edition).

Indications for Radical Prostatectomy

Radical prostatectomy (RPE) is a standard curative option for patients with localized prostate cancer and a life expectancy of at least 10 years. It should be offered to patients with intermediate- or high-risk disease and may be chosen for low-risk disease when active surveillance is not desired or appears unsuitable. Radical prostatectomy is the only curative treatment that has demonstrated a survival benefit over conservative management in a randomized trial (Bill-Axelson et al., 2011). In retrospective comparisons of large cohorts, radical prostatectomy has shown oncological advantages over radiotherapy, particularly in patients with intermediate- or high-risk disease (Boorjian et al., 2012; Chierigo et al., 2022); see also table D’Amico risk classification for prostate cancer.

Possible Surgical Techniques of Radical Prostatectomy

RPE can be performed using an open, laparoscopic, or robot-assisted approach. The dissection planes are identical for all techniques. Tumor stage, age, overall health, and the experience of the operating team are probably more important determinants of a favorable postoperative outcome than the surgical approach.

Comparative Trials

The interpretation of the numerous comparative studies is difficult. Surgical access primarily affects perioperative parameters. Minimally invasive procedures, particularly RALP, reduce blood loss and transfusion requirements and may accelerate recovery. The transperitoneal approach entails its own risks. Tumor biology, preoperative function, nerve sparing, surgical volume, and experience are more important than the access technique for continence, erectile function, and oncological control. Large comparative studies have found no relevant differences in potency, continence, or oncological cure (Dell’Oglio et al., 2020).

Role of Lymphadenectomy

Pelvic lymphadenectomy should not be performed in patients with low-risk disease. In patients with intermediate-risk disease, extended pelvic lymphadenectomy may be performed; in patients with high-risk disease, it should be performed. The boundaries are the external iliac artery laterally, the superior pubic ramus caudally, the medial umbilical ligament and bladder medially, the obturator nerve and pelvic wall deeply, and the ureter and bifurcation of the common iliac artery cranially. For extended lymphadenectomy, dissection is extended to the aorta, along the internal iliac artery, and presacrally. Randomized trials have not demonstrated an oncological benefit of extended lymphadenectomy (Lestingi et al., 2021; Touijer et al., 2021).

Nerve-Sparing Radical Prostatectomy

Intraoperative preservation of the cavernous nerves can maintain erectile function. Despite meticulous nerve sparing, microtrauma to the cavernous nerves initially causes a marked deterioration in erectile function. Nerve recovery is gradual, and erectile function may improve for up to 2 years after radical prostatectomy. In men who were potent before surgery, potency rates after nerve-sparing prostatectomy range from 30–60%.

From an oncological perspective, nerve sparing is challenging because no safety margin is present where the cavernous nerve runs to the penis within the periprostatic fascial layers. Select patients with a low risk of T3 disease on the side planned for nerve sparing. Favorable preoperative factors are a PSA level <10 ng/ml, no palpable tumor on the planned side, unremarkable or organ-confined findings on mpMRI, and no relevant Gleason pattern 4 component in ipsilateral biopsy cores.

Oncological Results of Radical Prostatectomy

In large series, 10-year recurrence-free survival after radical prostatectomy ranges from 29–83%, depending on clinical risk. Ten-year cancer-specific survival ranges from 89–99%; see table D’Amico risk classification for prostate cancer.

Independent pathological prognostic factors are Gleason grade, margin status, extraprostatic extension, seminal vesicle invasion, perineural invasion, and lymph node metastases.

Adjuvant Therapy After Prostatectomy

Neoadjuvant Androgen Deprivation Therapy

Randomized trials have not confirmed an oncological benefit of the former practice of neoadjuvant androgen deprivation therapy before radical prostatectomy. Although it improves individual pathological surrogate outcomes, such as tumor volume and margin status, it has not been shown to improve recurrence-free survival.

Neoadjuvant Chemotherapy for Locally Advanced Prostate Cancer

No established standard exists for neoadjuvant chemotherapy before RPE in locally advanced prostatic adenocarcinoma. For rare aggressive histologies, especially small-cell prostate cancer, platinum-based chemotherapy may be used as part of a multimodal treatment strategy.

Adjuvant Therapy for Lymph Node Metastases (pN1)

Management after RPE for pN1 disease should be individualized according to tumor burden, the extent of lymphadenectomy, postoperative PSA level, and comorbidity. Options include close PSA monitoring with restaging at PSA progression, immediate androgen deprivation therapy, or, in patients with higher tumor burden, combined ADT and radiotherapy to the prostatic fossa and regional lymphatic drainage pathways (Tilki et al., 2022). Depending on the risk profile and response, ADT may be paused after 2–3 years.

Adjuvant Androgen Deprivation Therapy for pN0 Disease

Do not administer adjuvant androgen deprivation therapy after radical prostatectomy in patients with pN0 M0 disease and an undetectable PSA level, even in the presence of relevant risk factors for subsequent recurrence, such as Gleason score ≥8, R1 resection, or pT3b disease.

Adjuvant Radiotherapy After R1 Resection

Routine adjuvant radiotherapy is no longer standard after R1 resection or pT3 disease. If postoperative PSA is undetectable, patients are generally monitored closely and early salvage radiotherapy is initiated at PSA progression. This approach avoids overtreatment and genitourinary toxicity in patients who do not require radiotherapy. Current studies demonstrate comparable progression-free survival with early salvage radiotherapy (Vale et al., 2020).

Biochemical Recurrence After Radical Prostatectomy

Biochemical recurrence after radical prostatectomy is defined as a confirmed PSA rise to >0.2 ng/ml after a previously undetectable or very low PSA level. Possible causes are local recurrence, regional lymph node metastases, or distant metastases.

Diagnosis

Rising PSA is highly sensitive; conventional imaging such as CT, bone scintigraphy, or TRUS cannot identify the cause and is therefore not indicated. PSMA PET is the standard diagnostic procedure at PSA levels of 0.3–0.5 ng/ml or higher. The following factors favor local recurrence rather than metastatic disease: no evidence of seminal vesicle invasion or lymph node metastases, Gleason score below 8, postoperative PSA nadir below the detection limit, PSA progression occurring more than 1 year after surgery, and a PSA doubling time of more than 10 months.

Prognosis of Untreated PSA Progression

Symptomatic metastases develop after a mean of 8 years; the mean interval from metastatic disease to death is 5 years. Prognosis is worse with earlier PSA progression or metastatic disease and with more rapid PSA increase. Patients with a PSA doubling time of more than 10 months, PSA recurrence more than 2 years after prostatectomy, primary Gleason score <8, no seminal vesicle invasion, and no lymph node metastases have a favorable prognosis. Depending on age, this group is suitable for active monitoring of PSA progression after prostatectomy.

External-Beam Radiotherapy for Suspected Local Recurrence

A PSA decline can be achieved in 20–80% of patients, depending on patient selection. Predictors of successful salvage radiotherapy are the exclusion of patients with suspected distant metastases, initiation of radiotherapy at a PSA level <0.5 ng/ml, and a dose of 66–70 Gy. In patients with unfavorable risk factors, particularly PSA >0.7 ng/ml before salvage radiotherapy, short PSA doubling time, Gleason score ≥8, seminal vesicle invasion, or early PSA recurrence, offer additional androgen deprivation therapy for 6 months (Carrie et al., 2019).

Treatment of Visible Metastases

Targeted radiotherapy for isolated lymph node or bone metastases, or surgical resection of a small number of isolated lymph node metastases, are experimental options to delay or avoid androgen deprivation therapy. In retrospective single-center series, radiotherapy (Farolfi et al., 2021) appears more successful than surgical treatment (Ploussard et al., 2019).

Androgen Deprivation Therapy for Systemic Progression

Androgen deprivation therapy is recommended for a short PSA doubling time (<3–6 months), symptomatic progression, or proven metastatic disease. Asymptomatic patients with slowly rising PSA can be observed until criteria for systemic therapy are met.





Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

References

Asimakopoulos, A. D.; Pereira Fraga, C. T.; Annino, F.; Pasqualetti, P.; Calado, A. A. & Mugnier, C. Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy.
J Sex Med, 2011, 8, 1503-1512

A. Bill-Axelson, L. Holmberg, M. Ruutu, M. Haggman, S. O. Andersson, S. Bratell, A. Spangberg, C. Busch, S. Nordling, H. Garmo, J. Palmgren, H. O. Adami, B. J. Norlen, and J. E. Johansson. Radical prostatectomy versus watchful waiting in early prostate cancer.
N Engl J Med, 352 (19): 1977–84, 2005.

A. Bill-Axelson, L. Holmberg, F. Filén, M. Ruutu, H. Garmo, C. Busch, S. Nordling, M. Häggman, S.-O. Andersson, S. Bratell, A. Spångberg, J. Palmgren, H.-O. Adami, J.-E. Johansson, and S. P. C. G. S. N. 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the scandinavian prostate cancer group-4 randomized trial.
J Natl Cancer Inst, 100 (16): 1144–1154, Aug 2008.
doi: rm10.1093/jnci/djn255.

Bill-Axelson, A.; Holmberg, L.; Ruutu, M.; Garmo, H.; Stark, J. R.; Busch, C.; Nordling, S.; Häggman, M.; Andersson, S.; Bratell, S.; Spångberg, A.; Palmgren, J.; Steineck, G.; Adami, H.; Johansson, J. & Investigators, S. P. C. G. Radical prostatectomy versus watchful waiting in early prostate cancer.
N Engl J Med, 2011, 364, 1708-1717.

Boorjian, S. A.; Eastham, J. A.; Graefen, M.; Guillonneau, B.; Karnes, R. J.; Moul, J. W.; Schaeffer, E. M.; Stief, C. & Zorn, K. C. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.
Eur Urol, 2012, 61, 664-675.

Coelho, R. F.; Rocco, B.; Patel, M. B.; Orvieto, M. A.; Chauhan, S.; Ficarra, V.; Melegari, S.; Palmer, K. J. & Patel, V. R. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers.
J Endourol, 2010, 24, 2003-2015

Epstein u.a. 1993 EPSTEIN, J. I. ; PIZOV, G. ; WALSH, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy.
In: Cancer
71 (1993), Nr. 11, S. 3582–93

Ficarra, V.; Novara, G.; Fracalanza, S.; D'Elia, C.; Secco, S.; Iafrate, M.; Cavalleri, S. & Artibani, W. A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution.
BJU Int, 2009, 104, 534-539

EAU Guidelines EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer, https://uroweb.org/guidelines/prostate-cancer/.

U. Ganswindt, A. Stenzl, M. Bamberg, and C. Belka. Adjuvant radiotherapy for patients with locally advanced prostate cancer-a new standard?
Eur Urol, 54 (3): 528–542, Sep 2008.
doi: rm10.1016/j.eururo.2008.06.059.
URL https://dx.doi.org/10.1016/j.eururo.2008.06.059.

Guazzoni, G.; Cestari, A.; Naspro, R.; Riva, M.; Centemero, A.; Zanoni, M.; Rigatti, L. & Rigatti, P. Intra- and peri-operative outcomes comparing radical retropubic and laparoscopic radical prostatectomy: results from a prospective, randomised, single-surgeon study.
Eur Urol, 2006, 50, 98-104.

Kang, D. C.; Hardee, M. J.; Fesperman, S. F.; Stoffs, T. L. & Dahm, P. Low quality of evidence for robot-assisted laparoscopic prostatectomy: results of a systematic review of the published literature.
Eur Urol, 2010, 57, 930-937.

Porpiglia, F.; Morra, I.; Lucci Chiarissi, M.; Manfredi, M.; Mele, F.; Grande, S.; Ragni, F.; Poggio, M. & Fiori, C. Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy.
Eur Urol, 2013, 63, 606-614

Leitlinienprogramm Onkologie (DGU, Deutsche Krebsgesellschaft, Deutsche Krebshilfe): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/

Sooriakumaran, P.; Pini, G.; Nyberg, T.; Derogar, M.; Carlsson, S.; Stranne, J.; Bjartell, A.; Hugosson, J.; Steineck, G. & Wiklund, P. N. Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial.
European urology, 2017

Wein, A. J.; Kavoussi, L. R.; Partin, A. P. & Peters, C. A. Campbell-Walsh Urology
. Elsevier, 2015. ISBN 978-1455775675.

Schröder, F.; Bangma, C.; Angulo, J. C.; Alcaraz, A.; Colombel, M.; McNicholas, T.; Tammela, T. L.; Nandy, I. & Castro, R. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
Eur Urol, 2013, 63, 779-787.

Thompson, I. M.; Tangen, C. M.; Paradelo, J.; Lucia, M. S.; Miller, G.; Troyer, D.; Messing, E.; Forman, J.; Chin, J.; Swanson, G.; Canby-Hagino, E. & Crawford, E. D. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
J Urol, 2009, 181, 956-962

D. Tilki, M.-H. Chen, J. Wu, H. Huland, M. Graefen, and A. V. D’Amico, “Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.,” J Clin Oncol, vol. 40, no. 20, pp. 2186–2192, 2022.

Trinh, Q.; Sammon, J.; Sun, M.; Ravi, P.; Ghani, K. R.; Bianchi, M.; Jeong, W.; Shariat, S. F.; Hansen, J.; Schmitges, J.; Jeldres, C.; Rogers, C. G.; Peabody, J. O.; Montorsi, F.; Menon, M. & Karakiewicz, P. I. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.
Eur Urol, 2012, 61, 679-685.



  Deutsche Version: Prostatakarzinom

Urology-Textbook.com – Choose the Ad-Free, Professional Resource

This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.

New release: The first edition of the Urology Textbook as an e-book—ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.